"Adoptive Engineered T Cell Trials To Achieve Cancer Killing"

Two multi-centre clinical trials to treat cancer using a form of cell therapy

About ATTACK

The ATTACK project involves two multi-centre clinical trials to treat cancer using a form of cell therapy. There are 8 hospital sites, as well as 2 cell manufacturing sites, 6 Universities and 4 companies involved across 6 countries in the EU. It is funded by the Framework 7 programme run by the EC.

Clinical Trials

There are two ATTACK clinical trials. Both these trials are Phase II clinical trials. A phase II clinical trial aims to find out whether a new treatment works in particular types of cancer. This involves looking at what side effects a new treatment may cause and how to manage them.

Contact ATTACK

ATTACK – Adoptive Engineered T Cell Trials to Achieve Cancer Killing.

The ATTACK team
Click here for contact details.

The ATTACK Partners
Click here to view ATTACK partners.